Market Closed - Nyse 04:00:01 2024-03-28 pm EDT 5-day change 1st Jan Change
14.44 USD +0.14% Intraday chart for Nevro Corp. +4.26% -32.90%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nevro 2024 Sales Expected Slightly Below Estimates, RBC Says MT
Wells Fargo Adjusts Price Target on Nevro to $17 From $20, Maintains Equal-Weight Rating MT
Baird Cuts Price Target on Nevro to $19 From $23, Maintains Neutral Rating MT
Oppenheimer Downgrades Nevro to Perform From Outperform, Removes $35 Price Target MT
RBC Lowers Price Target on Nevro to $18 From $20, Keeps Sector Perform Rating MT
Earnings Flash (NVRO) NEVRO Posts Q4 Revenue $116.2M, vs. Street Est of $116M MT
Engaged Capital Enters into Agreement with Nevro Corp CI
Transcript : Nevro Corp., Q4 2023 Earnings Call, Feb 21, 2024
Nevro Corp. Appoints Kirt P. Karros to Board of Directors and Audit Committee of the Board CI
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024 CI
Nevro Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
RBC Downgrades Nevro to Sector Perform From Outperform, Cuts Price Target to $20 From $23 MT
Transcript : Nevro Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Nevro to Cut 5% of Workforce in Restructuring, Says Preliminary Q4 Revenue Rose 2% MT
Truist Securities Adjusts Price Target on Nevro to $23 From $22, Maintains Hold Rating MT
Canaccord Genuity Downgrades Nevro to Hold From Buy, $23 Price Target MT
Nevro Corp. Enters into Certain Credit Agreement CI
Nevro Acquires Vyrsa Technologies, Closes Term Loan Credit Facility; Shares Rise After Hours MT
Nevro Corp. acquired Vyrsa Technologies for $75 million. CI
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain CI
Truist Securities Adjusts Price Target on Nevro to $17 From $18.50, Keeps Hold Rating MT
Morgan Stanley Cuts Price Target on Nevro to $18 From $23, Calls Q4 Guidance 'Wary,' Keeps Equalweight Rating MT
Transcript : Nevro Corp., Q3 2023 Earnings Call, Nov 01, 2023
Earnings Flash (NVRO) NEVRO Posts Q3 Revenue $103.9M, vs. Street Est of $95.9M MT
Chart Nevro Corp.
More charts
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
14.44 USD
Average target price
19.4 USD
Spread / Average Target
+34.35%
Consensus
  1. Stock
  2. Equities
  3. Stock Nevro Corp. - Nyse
  4. News Nevro Corp.
  5. Piper Sandler Adjusts Nevro's Price Target to $92 From $90, Maintains Neutral Rating